DEERFIELD, Ill.–(BUSINESS WIRE)–Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced it has completed its previously announced majority share acquisition of CareCentrix, Inc.—the leading independent home-centered platform that coordinates care to the home for health plans, patients and providers. The majority investment in CareCentrix accelerates Walgreens Health’s capabilities in delivering quality healthcare across a spectrum of settings including primary care, specialty pharmacy ca
Related Posts
CVC Capital Partners Aims for €700M Boost in Italian Pharma Outsourcing Giant Genetic: A Market Shift Analysis
Strategic Investment: CVC Capital Partners targets €700 million fundraising for Genetic, a leading Italian pharmaceutical outsourcing company, to drive organic and inorganic growth. Industry...
AlloVir-Kalaris Merger: A New Era in Retinal Disease Treatment
Strategic Focus: The merger between AlloVir and Kalaris Therapeutics creates a biotech entity laser-focused on developing innovative treatments for retinal diseases like neovascular age-related...
AlloVir & Kalaris Merge: Game-Changer in Retinal Disease Therapy
Strategic Consolidation: AlloVir and Kalaris Therapeutics merge to create a biotech powerhouse focused on retinal disease treatments. Market Potential: The global retinal disease market is projected...
Boston Scientific Boosts AF Treatment with Cortex Acquisition
Strategic Acquisition: Boston Scientific's acquisition of Cortex, Inc. expands its electrophysiology portfolio with the OptiMap System, a diagnostic mapping solution for complex atrial fibrillation...